Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Pacific Biosciences of California Inc’s stock clocked out at $1.78, down -7.05% from its previous closing price of $1.91. In other words, the price has decreased by -$7.05 from its previous closing price. On the day, 20.73 million shares were traded. PACB stock price reached its highest trading level at $1.98 during the session, while it also had its lowest trading level at $1.76.
Ratios:
To gain a deeper understanding of PACB’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.48 and its Current Ratio is at 8.65. In the meantime, Its Debt-to-Equity ratio is 19.40 whereas as Long-Term Debt/Eq ratio is at 19.40.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 18 ’25 when Van Oene Mark sold 26,836 shares for $1.31 per share. The transaction valued at 35,182 led to the insider holds 1,920,035 shares of the business.
MARK VAN OENE bought 26,836 shares of PACB for $35,174 on Aug 18 ’25. On May 19 ’25, another insider, Farmer Michele, who serves as the insider of the company, sold 5,195 shares for $1.00 each. As a result, the insider received 5,200 and left with 269,259 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PACB now has a Market Capitalization of 534659712 and an Enterprise Value of 962695744. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.46 while its Price-to-Book (P/B) ratio in mrq is 8.69. Its current Enterprise Value per Revenue stands at 6.167 whereas that against EBITDA is -4.265.
Stock Price History:
The Beta on a monthly basis for PACB is 2.34, which has changed by -0.1652174 over the last 52 weeks, in comparison to a change of 0.13355756 over the same period for the S&P500. Over the past 52 weeks, PACB has reached a high of $2.72, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is 15.73%, while the 200-Day Moving Average is calculated to be 29.95%.
Shares Statistics:
It appears that PACB traded 8.02M shares on average per day over the past three months and 11699950 shares per day over the past ten days. A total of 300.37M shares are outstanding, with a floating share count of 269.26M. Insiders hold about 10.36% of the company’s shares, while institutions hold 59.77% stake in the company. Shares short for PACB as of 1760486400 were 34508178 with a Short Ratio of 4.30, compared to 1757894400 on 45550788. Therefore, it implies a Short% of Shares Outstanding of 34508178 and a Short% of Float of 13.069999.
Earnings Estimates
The market rating of Pacific Biosciences of California Inc (PACB) is currently shaped by the ongoing analysis conducted by 2.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.12 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.53 and -$0.53 for the fiscal current year, implying an average EPS of -$0.53. EPS for the following year is -$0.49, with 6.0 analysts recommending between -$0.42 and -$0.54.
Revenue Estimates
In. The current quarter, 6 analysts expect revenue to total $41.64M. It ranges from a high estimate of $42.81M to a low estimate of $40.6M. As of. The current estimate, Pacific Biosciences of California Inc’s year-ago sales were $39.22MFor the next quarter, 6 analysts are estimating revenue of $41.71M. There is a high estimate of $44M for the next quarter, whereas the lowest estimate is $38.8M.
A total of 8 analysts have provided revenue estimates for PACB’s current fiscal year. The highest revenue estimate was $161.9M, while the lowest revenue estimate was $155.9M, resulting in an average revenue estimate of $158.22M. In the same quarter a year ago, actual revenue was $154.01MBased on 9 analysts’ estimates, the company’s revenue will be $180M in the next fiscal year. The high estimate is $185.8M and the low estimate is $165.2M.
